RIAlta-1 trial sponsor

Rialta Bio was a clinical-stage biotechnology company focused on developing oral small molecule therapies for inflammatory and immunological diseases. The company's lead program, RIAL-001, was a first-in-class oral small molecule inhibitor of the IL-4/IL-13 pathway, specifically targeting the IL-4 receptor alpha (IL-4Ra) subunit. Rialta Bio initiated the Phase 2 RIAlta-1 trial in patients with moderate to severe atopic dermatitis but terminated the study in late 2023 due to business decisions. The company was backed by Samsara BioCapital and aimed to provide an oral alternative to injectable biologics like dupilumab. Following the termination of its lead clinical program, the company appears to have ceased active operations.